Abstract
Many of the studies exploring dopamine (DA) function in depression have produced inconsistent findings. Contributors to this inconsistency include the diagnostic heterogeneity of major depressive disorder (MDD); failure to control for age, bipolar disorder, and comorbid diagnoses; and variation in patient medication treatment status at the time of the study. Despite this variability, there is now a convergence of data from animal models, genetics, neuroimaging, and human clinical trials that strengthens the case for DA dysfunction in the pathophysiology of major depression, at least in a significant subgroup of patients. This chapter comprehensively reviews the current evidence, with subsequent recommendations for future studies of dopaminergic signaling in depression and its treatment.
| Original language | English |
|---|---|
| Title of host publication | Dopamine Handbook |
| Publisher | Oxford University Press |
| ISBN (Print) | 9780199865543, 9780195373035 |
| DOIs | |
| State | Published - Feb 1 2010 |
| Externally published | Yes |
Fingerprint
Keywords
- Depression
- Dopamine dysfunction
- Major depressive disorder
- Pathophysiology
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
The Role of Dopamine in the Pathophysiology and Treatment of Major Depressive Disorder. / Dunlop, Boadie W.; Nemeroff, Charles.
Dopamine Handbook. Oxford University Press, 2010.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - The Role of Dopamine in the Pathophysiology and Treatment of Major Depressive Disorder
AU - Dunlop, Boadie W.
AU - Nemeroff, Charles
PY - 2010/2/1
Y1 - 2010/2/1
N2 - Many of the studies exploring dopamine (DA) function in depression have produced inconsistent findings. Contributors to this inconsistency include the diagnostic heterogeneity of major depressive disorder (MDD); failure to control for age, bipolar disorder, and comorbid diagnoses; and variation in patient medication treatment status at the time of the study. Despite this variability, there is now a convergence of data from animal models, genetics, neuroimaging, and human clinical trials that strengthens the case for DA dysfunction in the pathophysiology of major depression, at least in a significant subgroup of patients. This chapter comprehensively reviews the current evidence, with subsequent recommendations for future studies of dopaminergic signaling in depression and its treatment.
AB - Many of the studies exploring dopamine (DA) function in depression have produced inconsistent findings. Contributors to this inconsistency include the diagnostic heterogeneity of major depressive disorder (MDD); failure to control for age, bipolar disorder, and comorbid diagnoses; and variation in patient medication treatment status at the time of the study. Despite this variability, there is now a convergence of data from animal models, genetics, neuroimaging, and human clinical trials that strengthens the case for DA dysfunction in the pathophysiology of major depression, at least in a significant subgroup of patients. This chapter comprehensively reviews the current evidence, with subsequent recommendations for future studies of dopaminergic signaling in depression and its treatment.
KW - Depression
KW - Dopamine dysfunction
KW - Major depressive disorder
KW - Pathophysiology
UR - http://www.scopus.com/inward/record.url?scp=84918884323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84918884323&partnerID=8YFLogxK
U2 - 10.1093/acprof:oso/9780195373035.003.0040
DO - 10.1093/acprof:oso/9780195373035.003.0040
M3 - Chapter
SN - 9780199865543
SN - 9780195373035
BT - Dopamine Handbook
PB - Oxford University Press
ER -